Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).
This is because regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had sorafenib and the population size is small.
It is estimated that around 500 people in England are eligible for treatment with regorafenib each year.
The company has a commercial agreement (simple patient access scheme). This makes regorafenib available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme, contact access.team@bayer.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: